WO2006006691A3 - Nouvelle dispersion solide et son procede d'elaboration - Google Patents

Nouvelle dispersion solide et son procede d'elaboration Download PDF

Info

Publication number
WO2006006691A3
WO2006006691A3 PCT/JP2005/013099 JP2005013099W WO2006006691A3 WO 2006006691 A3 WO2006006691 A3 WO 2006006691A3 JP 2005013099 W JP2005013099 W JP 2005013099W WO 2006006691 A3 WO2006006691 A3 WO 2006006691A3
Authority
WO
WIPO (PCT)
Prior art keywords
solid dispersion
kinase inhibitor
map kinase
present
drug release
Prior art date
Application number
PCT/JP2005/013099
Other languages
English (en)
Other versions
WO2006006691A2 (fr
Inventor
Yoshihiro Omachi
Takashi Kurasawa
Original Assignee
Takeda Pharmaceutical
Yoshihiro Omachi
Takashi Kurasawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical, Yoshihiro Omachi, Takashi Kurasawa filed Critical Takeda Pharmaceutical
Publication of WO2006006691A2 publication Critical patent/WO2006006691A2/fr
Publication of WO2006006691A3 publication Critical patent/WO2006006691A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une dispersion solide renfermant (i) un médicament, (ii) des excipients, (iii) des plastifiants et (iv) des composés à libération contrôlée de médicaments. Selon cette invention, la solubilité de médicament insoluble ou peu soluble peut être améliorée et une fonction de contrôle de la libération de médicaments peut être fournie simultanément dans un processus d'élaboration unique. Ladite invention a également pour objet une dispersion solide possédant une composition uniforme permettant la libération soutenue de médicaments.
PCT/JP2005/013099 2004-07-09 2005-07-08 Nouvelle dispersion solide et son procede d'elaboration WO2006006691A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004203799A JP2007223903A (ja) 2004-07-09 2004-07-09 新規な固体分散体およびその製造方法
JP2004-203799 2004-07-09

Publications (2)

Publication Number Publication Date
WO2006006691A2 WO2006006691A2 (fr) 2006-01-19
WO2006006691A3 true WO2006006691A3 (fr) 2006-03-30

Family

ID=34979219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/013099 WO2006006691A2 (fr) 2004-07-09 2005-07-08 Nouvelle dispersion solide et son procede d'elaboration

Country Status (3)

Country Link
JP (1) JP2007223903A (fr)
TW (1) TW200608996A (fr)
WO (1) WO2006006691A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1992344A1 (fr) 2007-05-18 2008-11-19 Institut Curie P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2540317A4 (fr) * 2010-02-22 2014-04-16 Daiichi Sankyo Co Ltd Préparation solide à libération prolongée pour usage oral
EP2540318B1 (fr) 2010-02-22 2018-10-24 Daiichi Sankyo Company, Limited Préparation solide à libération prolongée pour utilisation orale
WO2015141662A1 (fr) 2014-03-18 2015-09-24 武田薬品工業株式会社 Dispersion solide
JPWO2020261619A1 (fr) * 2019-06-26 2020-12-30

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1180518A1 (fr) * 1999-04-23 2002-02-20 Takeda Chemical Industries, Ltd. Composes 5-pyridyle-1,3-azole, leur procede de fabrication et leur utilisation
US20030077322A1 (en) * 2000-05-20 2003-04-24 Lee Sang Deuk Solid dispersion system of pranlukast with improved dissolution and method for preparing the same
US20030181411A1 (en) * 2002-03-20 2003-09-25 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1180518A1 (fr) * 1999-04-23 2002-02-20 Takeda Chemical Industries, Ltd. Composes 5-pyridyle-1,3-azole, leur procede de fabrication et leur utilisation
US20030077322A1 (en) * 2000-05-20 2003-04-24 Lee Sang Deuk Solid dispersion system of pranlukast with improved dissolution and method for preparing the same
US20030181411A1 (en) * 2002-03-20 2003-09-25 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors

Also Published As

Publication number Publication date
TW200608996A (en) 2006-03-16
JP2007223903A (ja) 2007-09-06
WO2006006691A2 (fr) 2006-01-19

Similar Documents

Publication Publication Date Title
WO2006006691A3 (fr) Nouvelle dispersion solide et son procede d'elaboration
PL1663216T3 (pl) Kompozycje o zmodyfikowanym uwalnianiu zawierające takrolimus
UA93353C2 (ru) Производство фармацевтических композиций c быстрым высвобождением ha ochobe водонерастворимых лекарсвенных средств и фармацевтические композиции, полученные способом согласно изобретению
WO2005072079A3 (fr) Enrobage de medicaments a charge medicamenteuse elevee et procedes de fabrication
WO2008007152A3 (fr) Préparation de formulations pharmaceutiques
AU2003244632A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
IL183871A0 (en) Matrix type sustained-release preparation containing basic drug or salt thereof, and method for manufacturing the same
DE50000639D1 (de) Verfahren zur stabilisierung von polyvinylpyrrolidon-zubereitungen
ZA200301813B (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
AU2003300833A1 (en) Solid compositions with improved bio-availability of insoluble or poorly water soluble drugs and a corresponding process for preparing such
IL168266A (en) Nucleoside derivatives, processes for their preparation. pharmaceutical compositions comprising them and uses thereof for the manufacture of medicaments
WO2005009381A3 (fr) Preparation a liberation immediate de compositions pharmaceutiques labiles en milieu acide
WO2007072061A3 (fr) Formulation
AU2003244649A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2007075972A3 (fr) Formulations de chlorite et leurs procédés de préparation et d'utilisation
WO2006060384A3 (fr) Preparations de benzoxazoles substitues
WO2003086362A3 (fr) Comprimes d'hydrochlorure de bupropion stables
NO20005838D0 (no) Farmasöytisk multipartikkelform med programmert og styrt frigivning, samt fremstilling derav
HK1120417A1 (en) Stable nanoparticle formulations
WO2004069180A3 (fr) Compositions solides de dispersion
WO2004073686A3 (fr) Solutions de medicaments dans du menthol
WO2005077951A3 (fr) Derives 7h-pyrrolopyrimidine
WO2006085217A3 (fr) Adsorbes solides de medicaments hydrophobes
WO2003099228A8 (fr) Compositions et procedes d'inhibition de l'expression genetique au moyen de polynucleotides
WO2005110363A3 (fr) Systèmes et procédés pour préparer un dosage pharmaceutique en utilisant des compositions contenant des vésicules aqueuses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase